Handling HPV Vaccines And Screening: The Views Of 100 Authors

Landmark Vaccine Publication

Amsterdam, 21 September, 2006 - Elsevier is delighted to announce the publication of a unique supplement to the journal Vaccine: HPV Vaccines and Screening in the Prevention of Cervical Cancer. This special monograph provides a comprehensive and invaluable update for paediatricians, gynaecologists, health educators, policy decision makers, industry and major donor institutions worldwide.

With the arrival of the Human Papillomavirus (HPV) vaccines and the progressive introduction of HPV-based screening technology, the field of cervical cancer prevention is expanding into new areas of influence involving an ever-widening group of professionals. Starting with the offer of HPV vaccines to pre-adolescent girls and the optional vaccination of young and middle-age women, HPV vaccines may in some instances be recommended as a universal vaccine for both genders towards the prevention of cervical cancer. “An unprecedented and phenomenal challenge for Public Health in the 21st century”, according to Dr. Xavier Bosch, Guest Editor and driving force behind this monograph; “The background, the results, the challenges and a set of proposals are analyzed by a group of 100 independent experts, leaders in the various relevant fields”.

This monograph was officially launched during the 23rd International Papillomavirus Conference & Clinical Workshop in Prague, Czech Republic at the beginning of September 2006. The full version is available at the Vaccine website. Furthermore, this landmark publication will be available via the HINARI programme, the public-private initiative (launched by the World Health Organization) to bridge the digital divide in health information access . About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media Contacts
F. Xavier Bosch
Epidemiology and Cancer Registry Unit, IDIBELL
Institut Catala dÓncologia, Barcelona, Spain
+34.93.2607812
x.bosch@iconcologia.net

Floris de Hon
Journal Publisher, Immunology and Virology
Elsevier, Amsterdam, the Netherlands
+31.20.485.3280
f.hon@elsevier.com